Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study)

I. Abraham, K. MacDonald, MinKyoung Song, G. Ciesielski, C. Pacheco, Christopher Lee, M. Cholette, K. Kinsey, P. Speaks, C. Hermans, H. Brié, S. Reel, P. Van der Niepen, B. Yee, S. Vancayzeele

Research output: Contribution to journalArticle

Abstract

Background and aims: Obesity combined with hypertension places patients at greater risk for target-organ damage and cardiovascular disease. The purpose of this secondary analysis was to identify physician- and patient-levels determinants of blood pressure (BP) values and predictors of uncontrolled BP through subgroup analysis by body mass index (BMI). Methods and results: We conducted a subgroup analysis of 3006 patients with High-BMI (BMI >25kg/m2; n=2124) and Normal-BMI (BMI2; n=882) treated by 504 physicians and enrolled in PREVIEW, a Belgian prospective, multi-center, pharmaco-epidemiological study of 90-day second-line treatment with valsartan. Physician- and patient-level determinants of BP values and BP control were identified by means of hierarchical linear and logistic regression. Blood pressure values and control after 90 days of treatment were consistently lower for the High-BMI group. The 25.5% of variance in 90-day systolic and 28.3% of the variance in 90-day diastolic BP were attributable to physician-level determinants for the High-BMI group; versus 27.3% and 29.8% for the Normal-BMI group (ICC = 0.273 and 0.298, respectively). Determinants of 90-day BP values and predictors of uncontrolled BP varied considerably by BMI status. Conclusion: Several common and unique patient- and physician-level determinants of BP values and control were identified for the High-BMI and Normal-BMI groups. These findings highlight the need for differentiating healthcare interventions to account for patient and physician variables, particularly with respect to effective BP management in vulnerable populations.

Original languageEnglish (US)
Pages (from-to)314-322
Number of pages9
JournalNutrition, Metabolism and Cardiovascular Diseases
Volume23
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Body Mass Index
Blood Pressure
Physicians
Weights and Measures
Therapeutics
Valsartan
Vulnerable Populations
Epidemiologic Studies
Linear Models
Cardiovascular Diseases
Obesity
Logistic Models
Hypertension
Delivery of Health Care

Keywords

  • Angiotensin II receptor blocker
  • Body mass index
  • Effectiveness
  • Hypertension
  • Obesity
  • Pharmacoepidemiology
  • Valsartan

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study). / Abraham, I.; MacDonald, K.; Song, MinKyoung; Ciesielski, G.; Pacheco, C.; Lee, Christopher; Cholette, M.; Kinsey, K.; Speaks, P.; Hermans, C.; Brié, H.; Reel, S.; Van der Niepen, P.; Yee, B.; Vancayzeele, S.

In: Nutrition, Metabolism and Cardiovascular Diseases, Vol. 23, No. 4, 04.2013, p. 314-322.

Research output: Contribution to journalArticle

Abraham, I, MacDonald, K, Song, M, Ciesielski, G, Pacheco, C, Lee, C, Cholette, M, Kinsey, K, Speaks, P, Hermans, C, Brié, H, Reel, S, Van der Niepen, P, Yee, B & Vancayzeele, S 2013, 'Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study)', Nutrition, Metabolism and Cardiovascular Diseases, vol. 23, no. 4, pp. 314-322. https://doi.org/10.1016/j.numecd.2011.06.005
Abraham, I. ; MacDonald, K. ; Song, MinKyoung ; Ciesielski, G. ; Pacheco, C. ; Lee, Christopher ; Cholette, M. ; Kinsey, K. ; Speaks, P. ; Hermans, C. ; Brié, H. ; Reel, S. ; Van der Niepen, P. ; Yee, B. ; Vancayzeele, S. / Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study). In: Nutrition, Metabolism and Cardiovascular Diseases. 2013 ; Vol. 23, No. 4. pp. 314-322.
@article{cba5d61e7c854657bced976716c475bb,
title = "Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study)",
abstract = "Background and aims: Obesity combined with hypertension places patients at greater risk for target-organ damage and cardiovascular disease. The purpose of this secondary analysis was to identify physician- and patient-levels determinants of blood pressure (BP) values and predictors of uncontrolled BP through subgroup analysis by body mass index (BMI). Methods and results: We conducted a subgroup analysis of 3006 patients with High-BMI (BMI >25kg/m2; n=2124) and Normal-BMI (BMI2; n=882) treated by 504 physicians and enrolled in PREVIEW, a Belgian prospective, multi-center, pharmaco-epidemiological study of 90-day second-line treatment with valsartan. Physician- and patient-level determinants of BP values and BP control were identified by means of hierarchical linear and logistic regression. Blood pressure values and control after 90 days of treatment were consistently lower for the High-BMI group. The 25.5{\%} of variance in 90-day systolic and 28.3{\%} of the variance in 90-day diastolic BP were attributable to physician-level determinants for the High-BMI group; versus 27.3{\%} and 29.8{\%} for the Normal-BMI group (ICC = 0.273 and 0.298, respectively). Determinants of 90-day BP values and predictors of uncontrolled BP varied considerably by BMI status. Conclusion: Several common and unique patient- and physician-level determinants of BP values and control were identified for the High-BMI and Normal-BMI groups. These findings highlight the need for differentiating healthcare interventions to account for patient and physician variables, particularly with respect to effective BP management in vulnerable populations.",
keywords = "Angiotensin II receptor blocker, Body mass index, Effectiveness, Hypertension, Obesity, Pharmacoepidemiology, Valsartan",
author = "I. Abraham and K. MacDonald and MinKyoung Song and G. Ciesielski and C. Pacheco and Christopher Lee and M. Cholette and K. Kinsey and P. Speaks and C. Hermans and H. Bri{\'e} and S. Reel and {Van der Niepen}, P. and B. Yee and S. Vancayzeele",
year = "2013",
month = "4",
doi = "10.1016/j.numecd.2011.06.005",
language = "English (US)",
volume = "23",
pages = "314--322",
journal = "Nutrition, Metabolism and Cardiovascular Diseases",
issn = "0939-4753",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study)

AU - Abraham, I.

AU - MacDonald, K.

AU - Song, MinKyoung

AU - Ciesielski, G.

AU - Pacheco, C.

AU - Lee, Christopher

AU - Cholette, M.

AU - Kinsey, K.

AU - Speaks, P.

AU - Hermans, C.

AU - Brié, H.

AU - Reel, S.

AU - Van der Niepen, P.

AU - Yee, B.

AU - Vancayzeele, S.

PY - 2013/4

Y1 - 2013/4

N2 - Background and aims: Obesity combined with hypertension places patients at greater risk for target-organ damage and cardiovascular disease. The purpose of this secondary analysis was to identify physician- and patient-levels determinants of blood pressure (BP) values and predictors of uncontrolled BP through subgroup analysis by body mass index (BMI). Methods and results: We conducted a subgroup analysis of 3006 patients with High-BMI (BMI >25kg/m2; n=2124) and Normal-BMI (BMI2; n=882) treated by 504 physicians and enrolled in PREVIEW, a Belgian prospective, multi-center, pharmaco-epidemiological study of 90-day second-line treatment with valsartan. Physician- and patient-level determinants of BP values and BP control were identified by means of hierarchical linear and logistic regression. Blood pressure values and control after 90 days of treatment were consistently lower for the High-BMI group. The 25.5% of variance in 90-day systolic and 28.3% of the variance in 90-day diastolic BP were attributable to physician-level determinants for the High-BMI group; versus 27.3% and 29.8% for the Normal-BMI group (ICC = 0.273 and 0.298, respectively). Determinants of 90-day BP values and predictors of uncontrolled BP varied considerably by BMI status. Conclusion: Several common and unique patient- and physician-level determinants of BP values and control were identified for the High-BMI and Normal-BMI groups. These findings highlight the need for differentiating healthcare interventions to account for patient and physician variables, particularly with respect to effective BP management in vulnerable populations.

AB - Background and aims: Obesity combined with hypertension places patients at greater risk for target-organ damage and cardiovascular disease. The purpose of this secondary analysis was to identify physician- and patient-levels determinants of blood pressure (BP) values and predictors of uncontrolled BP through subgroup analysis by body mass index (BMI). Methods and results: We conducted a subgroup analysis of 3006 patients with High-BMI (BMI >25kg/m2; n=2124) and Normal-BMI (BMI2; n=882) treated by 504 physicians and enrolled in PREVIEW, a Belgian prospective, multi-center, pharmaco-epidemiological study of 90-day second-line treatment with valsartan. Physician- and patient-level determinants of BP values and BP control were identified by means of hierarchical linear and logistic regression. Blood pressure values and control after 90 days of treatment were consistently lower for the High-BMI group. The 25.5% of variance in 90-day systolic and 28.3% of the variance in 90-day diastolic BP were attributable to physician-level determinants for the High-BMI group; versus 27.3% and 29.8% for the Normal-BMI group (ICC = 0.273 and 0.298, respectively). Determinants of 90-day BP values and predictors of uncontrolled BP varied considerably by BMI status. Conclusion: Several common and unique patient- and physician-level determinants of BP values and control were identified for the High-BMI and Normal-BMI groups. These findings highlight the need for differentiating healthcare interventions to account for patient and physician variables, particularly with respect to effective BP management in vulnerable populations.

KW - Angiotensin II receptor blocker

KW - Body mass index

KW - Effectiveness

KW - Hypertension

KW - Obesity

KW - Pharmacoepidemiology

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=84875067519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875067519&partnerID=8YFLogxK

U2 - 10.1016/j.numecd.2011.06.005

DO - 10.1016/j.numecd.2011.06.005

M3 - Article

VL - 23

SP - 314

EP - 322

JO - Nutrition, Metabolism and Cardiovascular Diseases

JF - Nutrition, Metabolism and Cardiovascular Diseases

SN - 0939-4753

IS - 4

ER -